Corrigendum: Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema
Gaixia Zhai, Chao Sun, Xia Zhang, Yuanzhen Su
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBiosimilars and Bioanalytical Methods · Retinal Diseases and Treatments · Retinal and Optic Conditions
In the published article, the reference for (5) was incorrectly written as “Georgalas, L, Tservakis, I, Kiskira, EE, Petrou, P, Papaconstantinou, D, and Kanakis, M. Efficacy and safety of intravitreal dexamethasone implant in treatment-resistant diabetic macular edema: six-month results. Cesk Slov Oftalmol. (2025) 81:330–7. doi: 10.31348/2025/4.” It should be “Berhuni M, Yılmaz İE, Gizem GS, Özcan ZÖ, Doğan L. Efficacy and safety of intravitreal dexamethasone implant in treatment-resistant diabetic macular edema: six-month results. Cesk Slov Oftalmol. (2025) 81:1–6. doi: 10.31348/2025/4.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
The reference list from the paper itself. Each links out to its DOI / PubMed record.